177Lu-JH04

177Lu-JH04 is a novel therapeutic radiopharmaceutical classified as a radionuclide drug conjugate (RDC) that targets fibroblast activation protein (FAP), which is highly expressed on cancer-associated fibroblasts (CAFs) in the tumor microenvironment of many malignant tumors. By binding to FAP, 177Lu-JH04 delivers targeted beta radiation from the lutetium-177 isotope directly to FAP-positive tumor stroma, aiming to damage and kill cancer cells while sparing most normal tissues. Preclinical studies have shown high stability, specific tumor accumulation, strong binding affinity for FAP, and favorable safety and selectivity profiles. The drug is being developed primarily for advanced cancers with high FAP expression after exhaustion of standard therapies[1][2][5].